Sana Biotechnology：建立在進入臨床一期前期的 10 億美元市值基礎 (SANA)
· seekingalpha.com
Sana Biotechnology 的核心資產仍為 SC291，現已從血液腫瘤轉向開發於嚴重自體免疫疾病。了解為何 SANA 股票被評為「買進」。
Sana Biotechnology, Inc. ( SANA ) has recently undergone a big pipeline reset . Up to 2024, they mainly focused on oncology, specifically blood cancers, but aft...